Cost-effectiveness Analysis of Applying Camrelizumab as Second-Line Therapy for the Treatment of Advanced Hepa- tocellular Carcinoma
SHI Feng-hao
MENG Rui
WANG Zi-jing
Machine-generated Keywords：
Publication Date：2021-02-05
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 62-65 )